JUL 29·SEC EDGARLow
Altman Peter purchased $4K of BCDA
Altman Peter (President and CEO) purchased 5,000 shares of BioCardia, Inc. (BCDA) at $0.78 on 2026-07-29.
StockNASDAQ · US · USDHealthcare · Biotechnology
$BCDA
BioCardia, Inc.
Price · $BCDAvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $BCDA in the last 7 days.
Insider · 30dAll trades →
- Buys
- $9K 5 txs
- Sells
- — 0 txs
Altman Peter5× · $9K
10b5-1 plan0%
Top stories · $BCDAMore →
JUL 20·SEC EDGAR
Altman Peter purchased $415 of BCDA
Altman Peter (President and CEO) purchased 500 shares of BioCardia, Inc. (BCDA) at $0.83 on 2026-07-17.
JUL 15·SEC EDGAR
Altman Peter purchased $4K of BCDA
Altman Peter (President and CEO) purchased 4,300 shares of BioCardia, Inc. (BCDA) at an average of $0.87 ($0.86–$0.88) across 2 trades over 2026-07-14 to 2026-07-15.
BCDA sentiment & insider activity
Recent BCDA coverage spans insider activity and financial news.
In the last 30 days, BCDA insiders filed 5 SEC Form 4 transactions — 5 purchases ($9K) and no sales. The most active reporter was Altman Peter, President and CEO, with 5 filings.
What's driving BCDA
The filing signals insider buying, but it is a small, non-guidance datapoint with limited direct implications for near-term fundamentals.
The filing is a direct insider buy, but it is small in dollar terms and lacks a 10b5-1 plan, so it is more sentiment than fundamentals.
This is an insider buy, but it is not a fundamental catalyst like guidance, trial results, or a deal. It may modestly support sentiment if traders view it as confidence in near-term prospects.
Insider buying is a modest bullish signal, but it is not a fundamental catalyst like guidance, trial results, or financing.
The filing is a fresh insider buy, but it is small in dollar terms and does not change fundamentals by itself.
alphai scores every news story that mentions BCDA with an AI model for sentiment and relevance, and aggregates insider trades from BioCardia, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $BCDA
Score
Altman Peter purchased $4K of BCDA
Altman Peter (President and CEO) purchased 5,000 shares of BioCardia, Inc. (BCDA) at $0.78 on 2026-07-29.
2 min readAltman Peter purchased $415 of BCDA
Altman Peter (President and CEO) purchased 500 shares of BioCardia, Inc. (BCDA) at $0.83 on 2026-07-17.
2 min readAltman Peter purchased $4K of BCDA
Altman Peter (President and CEO) purchased 4,300 shares of BioCardia, Inc. (BCDA) at an average of $0.87 ($0.86–$0.88) across 2 trades over 2026-07-14 to 2026-07-15.
2 min readAltman Peter purchased $7K of BCDA
Altman Peter (President and CEO) purchased 7,500 shares of BioCardia, Inc. (BCDA) at an average of $0.96 ($0.90–$0.97) across 3 trades over 2026-07-08 to 2026-07-10.
2 min readAltman Peter purchased $5K of BCDA
Altman Peter (President and CEO) purchased 5,400 shares of BioCardia, Inc. (BCDA) at $0.96 on 2026-07-08.
1 min readSTERTZER SIMON H purchased $104K of BCDA
STERTZER SIMON H purchased 109,200 shares of BioCardia, Inc. (BCDA) at an average of $0.95 ($0.92–$1.00, $0.10M total) across 2 trades over 2026-06-22 to 2026-06-23.
2 min readAltman Peter purchased $2K of BCDA
Altman Peter (President and CEO) purchased 2,300 shares of BioCardia, Inc. (BCDA) at an average of $0.89 ($0.85–$0.96) across 2 trades over 2026-06-17 to 2026-06-18.
2 min read
BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities
BioCardia (Nasdaq: BCDA) CEO Peter Altman told shareholders the company’s top priority is submitting CardiAMP Cell Therapy for ischemic HFrEF to Japan’s PMDA, with a planned submission by end-2026 and potential initial approval for a subgroup of 20,000 of Japan’s estimated 300,000 patients. The FDA may support Premarket Approval for the U.S. CardiAMP HF II confirmatory trial. Altman also outlined plans to advance Helix/Heart3D delivery and its allogeneic MSC platform, supported by a recent capit
4 min readAltman Peter purchased $4K of BCDA
Altman Peter (President and CEO) purchased 5,000 shares of BioCardia, Inc. (BCDA) at $0.85 on 2026-06-09.
2 min readBioCardia (NASDAQ: BCDA) CEO adds 1,700 shares in May open‑market buys
BioCardia, Inc. (NASDAQ: BCDA) President and CEO Peter Altman recently purchased 1,700 shares of the company's common stock through open-market transactions. These purchases, totaling $1,570, involved 200 shares bought at $0.95 and 1,500 shares at $0.92, increasing his direct holdings to 293,266 shares. The transactions, detailed in a Form 4 SEC filing, reflect insider confidence in the biotechnology company.
2 min read